Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Similar documents
Atreca Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Lockheed Martin Missiles and Fire Control - Strategy, SWOT and Corporate Finance Report

DEC - Riyadh PP11 Gas Fired Power Plant - Saudi Arabia - Construction Project Profile

Alopecia - Pipeline Review, H2 2015

Statement Regarding Engineer s Report on the Load Control Relay RAB Adjustment for Waipa Networks

Pharma Investment in Digital Health: Strategies for success

Real World Evidence in Europe

Mediwales Finance and Funding Event:

# $ pages In Stock. Report Description

REFERENCE CODE GDHC1184DFR PUBLICATION DATE JUNE 2013

BIOMINAS BRASIL. Your ideal partner to succeed in life sciences in Latin America Dedicated to create and develop business in life sciences since 1990

Round 8 Guidelines. Overview & Objective

Global Location Trends: Asia-Pacific Facts & Figures

CAMBRIDGE ADVANCED LEADERSHIP PROGRAMME (ALP)

Forward-Looking Statements

The Legal Business Awards 2018

IPO Launch Presentation by Philip Lim. Megachem Limited

NOVEMBER Victorian Startup Investment Snapshot

The Legal Business Awards 2017

Retrospective Chart Review Studies

ZICO HOLDINGS INC. AND STAMFORD LAW CORPORATION TO FORM JOINT VENTURE

Embark on your membership journey. Apply now... MEMBER BENEFITS

Modernizing Hospital Adverse Event Reporting

Australia s Life Sciences Sector Snapshot 2017

MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY

Partnering with Technology Companies to Advance Medical Device Innovation

General information. Name: Colin Sainsbury

Physician / Investigator. Over 40% of clinical trial data are entered into health record and EDC 1

TABLE OF CONTENTS. 1.2 Market Overview Introduction Industry Drivers Market Size 1-5

Guangdong Kanghua Healthcare Co. Ltd. 廣東康華醫療股份有限公司

The 3E Principle of Outsourcing

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure

Outsourcing our approach and experience

What next for Life Sciences? Vir Lakshman

Innovation Academy. Business skills courses for Imperial Entrepreneurs

A patient experience

The Software Industry Financial Report

ADMINISTRATION OF INSULIN IN THE COMMUNITY BY ATTENDANT CARE SUPPORT WORKERS

Implementing Changes in Pharmacovigilance Regulations. Presented by Dr Ennis H Lee, Senior Partner, TranScrip 14 June 2016

Pharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist

Australia s premier University-based research impact accelerator program

China Medical Robot Industry Report, Oct. 2015

Q Manpower. Employment Outlook Survey New Zealand. A Manpower Research Report

The role of national development banks un fostering SME access to finance

Sponsorship Proposal

Enterprise Supplier Development Framework. Chemin Partnership to service ESD Programme

Takeda akeda Research esearch Investment, Inc. nc. 435 Tasso Street, Suite 300 Palo Alto, CA94301 USA. Tel: +1 (650)

Strategies for attracting healthcare venture capital

The business is on a growth trajectory and central to this growth is the need to attract successful recruitment consultants.

ENTREPRENEURSHIP & ACCELERATION

Enterprise Development Fund. Purpose and Process. July 2012

What information does Genome.One collect about you and why?

Hitwise US Research Note: Measuring Web 2.0 Consumer Participation

To order Asia Pacific Pay-TV & Broadband Markets 2008, complete and return the order form on page 13

R&D Tax Credits. Energy and natural resources sector

Access needs and Grants for the Arts

TRIBECA COMPANY PROFILE 2016

Members Annual Subscription 2017

For personal use only

BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS

Creative Minds. Scholarship for current undergraduate students

ABMU Health Board Research and Development Strategy

Avi-Tech Electronics launches Initial Public Offering of

Acquisition of aufeminin.com

Start Ups and their Impact on Smart Buildings

Early Access Programs (EAPs)

Guild Property Investors

Helping you capture new markets

EXECUTIVE EDUCATION in Life Sciences

Guide For Prospective Authors Submitting Manuscript Proposals

Latin America: An Evolving Regulatory Environment September 15, Mapi 2015, All Rights Reserved

Manpower Employment Outlook Survey Ireland. A Manpower Research Report

PwC s Accelerator Local to Global

Rationale for Acquisition of St. Paul and Zale Lipshy University Hospitals. History of the UTSW- University Hospital Relationship

Building a Successful International Franchise Program

Report Author. Tim Evans Managing Director Tel: +44 (0)

Bill Coakley, Senior Director, Supply Chain Management, SciClone Pharmaceuticals. Tom Heebink, Business Development/Strategic Alliances/West, BIO

Capio Disclosures September Analyst certification. Regulation. Conflicts of interest

IT Outsourcing Contracts: Crunching the Numbers

Human Capital Services Report SPRING 2012

Originating Component: Office of the General Counsel of the Department of Defense. Effective: February 27, Releasability:

The Language Services Market: 2013

Perspective: Case Study Emerging Care Management Models in Developing Countries

THE CPA AUSTRALIA ASIA-PACIFIC SMALL BUSINESS SURVEY 2016

For personal use only

Investor Presentation Q1 FY 2017

NHS SCOTLAND APPLICATION FOR REIMBURSEMENT / PERMISSION TO TRAVEL FOR TREATMENT IN THE EUROPEAN ECONOMIC AREA

Cambridge: driving growth in life sciences Exploring the value of knowledge-clusters on the UK economy and life sciences sector

Austal Ltd Andrew Bellamy Chief Executive Officer

PPEA Guidelines and Supporting Documents

Welcome to Ascom Wireless Solutions. Integrated Workflow Intelligence. Kent Badenfors, Area Sales manager CEE and Brazil

Driving Business Value for Healthcare Through Unified Communications

Private Hospital Services

SERVICE LEVEL AGREEMENT: University of Arkansas for Medical Sciences OFFICE OF SPONSORED PROGRAMS ADMINISTRATIVE NETWORK (OSPAN)

Request for information on a proposal to fund compression bandages and hosiery for the treatment of venous leg ulcers

Life Sciences Outlook

AST Research Network Career Development Grants: 2019 Faculty Development Research Grant

Why aren t we all using Real-World Evidence if it is so insightful and powerful? Because it is difficult to generate. Introducing E360 by IMS Health

UBM CAPITAL MARKETS DAY

2009 Market Predictions October 2008 Topics: FAO, Global Sourcing, HRO, ITO, PO, and Supplier Intelligence

Transcription:

Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com 2

Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary Specialised Therapeutics Australia Pty. Ltd. (STA) is a bio-pharmaceutical company that develops and commercializes therapies and technologies for unmet medical needs. The company s product portfolio includes Abraxane, Gliolan, Oncotype DX, Iclusig, Oncotype DX Prostate and Aloxi. Its pipeline products include Anamorelin and Iluvien among others. STA also offers services such as pharmacovigilance, investigator sponsored clinical trials, warehousing and distribution, commercialisation and marketing and local document filing, regulatory approval and registration. Its target therapy areas include oncology, hematology, urology, CNS and endocrinology. The company s partner portfolio includes Ariad, Celgene, Genomic Health, Helsinn, Alimera Sciences, Photonamic, and Grupo Zeltia among others. It markets its products across Australia and New Zealand. STA is headquartered in Melbourne, Victoria, Australia. Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma etrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. 3

- Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Additional Details Publisher : Global Data Reference : GDPH139160D Number of Pages : 26 Report Format : PDF 4

Publisher Information : 5

Table Of Contents for Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Table of Contents Table of Contents 2List of Tables 3List of Figures 4Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8Specialised Therapeutics Australia Pty. Ltd., Medical Devices Deals, 2010 to YTD 2016 9Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deal Details 11Partnerships 11Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 11Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 13Licensing Agreements 14Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 14Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 15Helsinn Healthcare Enters Into Licensing Agreement With Specialised Therapeutics Australia For Anamorelin 16Optimer Pharma Enters Into Licensing Agreement With Specialised Therapeutics For Fidaxomicin 18Helsinn Enters Into Licensing Agreement With Specialised Therapeutics 20Specialised Therapeutics Australia Enters Into Licensing Agreement With photonamic For Gliolan 21Specialised Therapeutics Enters Into Licensing Agreement With Helsinn For Palonosetron 22Specialised Therapeutics Australia Pty. Ltd. - Key Competitors 23Key Employees 24Locations And Subsidiaries 25Head Office 25Appendix 26Methodology 26About GlobalData 26Contact Us 26Disclaimer 26 6

List Of Tables in Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Tables Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Key Facts 1 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7 Specialised Therapeutics Australia Pty. Ltd., Deals By Therapy Area, 2010 to YTD 2016 8 Specialised Therapeutics Australia Pty. Ltd., Medical Devices Deals, 2010 to YTD 2016 9 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10 Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 11 Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 13 Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 14 Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 15 Helsinn Healthcare Enters Into Licensing Agreement With Specialised Therapeutics Australia For Anamorelin 16 Optimer Pharma Enters Into Licensing Agreement With Specialised Therapeutics For Fidaxomicin 18 Helsinn Enters Into Licensing Agreement With Specialised Therapeutics 20 Specialised Therapeutics Australia Enters Into Licensing Agreement With photonamic For Gliolan 21 Specialised Therapeutics Enters Into Licensing Agreement With Helsinn For Palonosetron 22 Specialised Therapeutics Australia Pty. Ltd., Key Competitors 23 Specialised Therapeutics Australia Pty. Ltd., Key Employees 24 7

List Of Figures, Charts and Diagrams in Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile List of Figures Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7 Specialised Therapeutics Australia Pty. Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8 Specialised Therapeutics Australia Pty. Ltd., Medical Devices Deals, 2010 to YTD 2016 9 8

How to Buy... Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Email: Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $250 Single User Price $500 Site License Price $750 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will email you the invoice with a payment link) Direct Wire Transfer (we will email you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0)1300 321501 We will be delighted to give you our personal attention. 9